{"id":348450,"date":"2026-11-16T13:59:32","date_gmt":"2026-11-16T08:29:32","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=348450"},"modified":"2026-11-16T13:59:32","modified_gmt":"2026-11-16T08:29:32","slug":"ajanta-pharma-share-price-target-2027-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/","title":{"rendered":"Ajanta Pharma Share Price Target 2027: Is Rs 3,752 Realistic? Bull Case Points to Rs 4,542"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Ajanta Pharma share price Rs 3,355.80 (16 November 2026). Base target Rs 3,752, bull Rs 4,542, downside risk Rs 2,628. PE 32.50. 52W range Rs 2,445.80 to Rs 3,796.00.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Ajanta Pharma share price target for 2027 is Rs 3,752, about 11.8% above the current price of Rs 3,355.80. The bull case is Rs 4,542, and the downside risk level, which is not a target, is Rs 2,628. The base case assumes earnings per share grow 14.2% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 32.50. These are model-based estimates built from reported financials, not guaranteed outcomes.<\/p>\n<\/p><\/div>\n<p>Investors weighing a Ajanta Pharma target price for 2027 should start with where the stock sits today. At Rs 3,355.80 on 16 November 2026, it is 11.6% below its 52-week high of Rs 3,796.00 and 37.2% above its 52-week low of Rs 2,445.80. That range spans 55% from low to high, so the entry point matters as much as the Ajanta Pharma price forecast itself.<\/p>\n<p>This article builds the Ajanta Pharma share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=ajanta-pharma-share-price-target-2027\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Ajanta_Pharma_Stock_Analysis_Company_Overview_and_Key_Stats\" title=\"Ajanta Pharma Stock Analysis: Company Overview and Key Stats\">Ajanta Pharma Stock Analysis: Company Overview and Key Stats<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Why_Is_Ajanta_Pharma_Share_Price_Target_Set_at_Rs_3752_for_2027\" title=\"Why Is Ajanta Pharma Share Price Target Set at Rs 3,752 for 2027?\">Why Is Ajanta Pharma Share Price Target Set at Rs 3,752 for 2027?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Earnings_Growth_Behind_the_Ajanta_Pharma_Target_Price_Five_Years_of_Results\" title=\"Earnings Growth Behind the Ajanta Pharma Target Price: Five Years of Results\">Earnings Growth Behind the Ajanta Pharma Target Price: Five Years of Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Margins_and_the_Latest_Quarter\" title=\"Margins and the Latest Quarter\">Margins and the Latest Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Balance_Sheet_and_Cash_Flow\" title=\"Balance Sheet and Cash Flow\">Balance Sheet and Cash Flow<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Valuation_Check_for_the_Ajanta_Pharma_Stock_Target_PE_Price_to_Book_and_ROE\" title=\"Valuation Check for the Ajanta Pharma Stock Target: PE, Price to Book and ROE\">Valuation Check for the Ajanta Pharma Stock Target: PE, Price to Book and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Shareholding_Pattern_and_Institutional_Holding\" title=\"Shareholding Pattern and Institutional Holding\">Shareholding Pattern and Institutional Holding<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Ajanta_Pharma_Share_Price_Targets_for_the_Short_Term_and_12_Months\" title=\"Ajanta Pharma Share Price Targets for the Short Term and 12 Months\">Ajanta Pharma Share Price Targets for the Short Term and 12 Months<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Short_Term_Ajanta_Pharma_Stock_Target_Levels_Technical_Setup\" title=\"Short Term Ajanta Pharma Stock Target Levels: Technical Setup\">Short Term Ajanta Pharma Stock Target Levels: Technical Setup<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#12_Month_Ajanta_Pharma_Target_Price_for_2027\" title=\"12 Month Ajanta Pharma Target Price for 2027\">12 Month Ajanta Pharma Target Price for 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#How_EPS_Growth_and_PE_Multiple_Change_the_Ajanta_Pharma_Target_Price\" title=\"How EPS Growth and PE Multiple Change the Ajanta Pharma Target Price\">How EPS Growth and PE Multiple Change the Ajanta Pharma Target Price<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Bull_Case_and_Downside_Risk_for_Ajanta_Pharma_Stock_Target_in_2027\" title=\"Bull Case and Downside Risk for Ajanta Pharma Stock Target in 2027\">Bull Case and Downside Risk for Ajanta Pharma Stock Target in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Bull_Case_Rs_4542\" title=\"Bull Case Rs 4,542\">Bull Case Rs 4,542<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Downside_Risk_Level_Rs_2628\" title=\"Downside Risk Level Rs 2,628\">Downside Risk Level Rs 2,628<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Key_Risks_to_the_Ajanta_Pharma_Target_Price_for_2027\" title=\"Key Risks to the Ajanta Pharma Target Price for 2027\">Key Risks to the Ajanta Pharma Target Price for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Growth_Slowdown_Risk_for_the_Ajanta_Pharma_Price_Target\" title=\"Growth Slowdown Risk for the Ajanta Pharma Price Target\">Growth Slowdown Risk for the Ajanta Pharma Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Liquidity_and_Size_Risk\" title=\"Liquidity and Size Risk\">Liquidity and Size Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Valuation_and_Margin_Risk\" title=\"Valuation and Margin Risk\">Valuation and Margin Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Market_and_Technical_Risk\" title=\"Market and Technical Risk\">Market and Technical Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#How_to_Invest_in_Ajanta_Pharma\" title=\"How to Invest in Ajanta Pharma\">How to Invest in Ajanta Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#FAQs_on_Ajanta_Pharma_Share_Price_Target_2027\" title=\"FAQs on Ajanta Pharma Share Price Target 2027\">FAQs on Ajanta Pharma Share Price Target 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#What_is_the_Ajanta_Pharma_share_price_target_for_2027\" title=\"What is the Ajanta Pharma share price target for 2027?\">What is the Ajanta Pharma share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#What_is_the_Ajanta_Pharma_share_price_today\" title=\"What is the Ajanta Pharma share price today?\">What is the Ajanta Pharma share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Is_Ajanta_Pharma_a_buy_or_sell_at_the_current_price\" title=\"Is Ajanta Pharma a buy or sell at the current price?\">Is Ajanta Pharma a buy or sell at the current price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#What_are_the_bull_case_target_and_downside_risk_level_for_Ajanta_Pharma_shares\" title=\"What are the bull case target and downside risk level for Ajanta Pharma shares?\">What are the bull case target and downside risk level for Ajanta Pharma shares?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#What_are_the_main_risks_to_the_Ajanta_Pharma_price_target\" title=\"What are the main risks to the Ajanta Pharma price target?\">What are the main risks to the Ajanta Pharma price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#What_is_the_PE_ratio_of_Ajanta_Pharma_and_how_does_it_compare_with_the_industry\" title=\"What is the PE ratio of Ajanta Pharma and how does it compare with the industry?\">What is the PE ratio of Ajanta Pharma and how does it compare with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#Who_owns_Ajanta_Pharma_and_what_is_the_promoter_holding\" title=\"Who owns Ajanta Pharma, and what is the promoter holding?\">Who owns Ajanta Pharma, and what is the promoter holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/ajanta-pharma-share-price-target-2027-2\/#What_were_Ajanta_Pharmas_latest_quarterly_results\" title=\"What were Ajanta Pharma&#8217;s latest quarterly results?\">What were Ajanta Pharma&#8217;s latest quarterly results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_Stock_Analysis_Company_Overview_and_Key_Stats\"><\/span><strong>Ajanta Pharma Stock Analysis: Company Overview and Key Stats<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ajanta Pharma (NSE: AJANTPHARM) has a market capitalisation of Rs 41,042 crore. In FY26 it reported revenue of Rs 5,625 crore and net profit of Rs 1,056 crore. The table collects the figures the Ajanta Pharma share price target is built on.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/ajantpharm\/ajanta-pharma-ltd-share-price-today\">Ajanta Pharma<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>AJANTPHARM<\/td>\n<\/tr>\n<tr>\n<td>CMP (16 November 2026)<\/td>\n<td>Rs 3,355.80<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 3,796.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 2,445.80<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 41,042 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>32.50<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>40.65<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>8.45<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>25.99%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.03<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 101.06<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.86%<\/td>\n<\/tr>\n<tr>\n<td>12-Month Base Target<\/td>\n<td>Rs 3,752<\/td>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 4,542<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk Level (not a target)<\/td>\n<td>Rs 2,628<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_Ajanta_Pharma_Share_Price_Target_Set_at_Rs_3752_for_2027\"><\/span><strong>Why Is Ajanta Pharma Share Price Target Set at Rs 3,752 for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The arithmetic is short. Trailing EPS of Rs 101.06 grown for one year gives a forward EPS estimate of Rs 115.44, and multiplying it by the unchanged PE of 32.50 gives the Rs 3,752 base-case Ajanta Pharma stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Growth_Behind_the_Ajanta_Pharma_Target_Price_Five_Years_of_Results\"><\/span><strong>Earnings Growth Behind the Ajanta Pharma Target Price: Five Years of Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ajanta Pharma grew revenue from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew more slowly, from Rs 712.68 crore to Rs 1,056 crore (10.3% a year), which points to margin pressure alongside the sales growth.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Financial Year<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<th>EPS (Rs)<\/th>\n<th>Dividend per Share (Rs)<\/th>\n<\/tr>\n<tr>\n<td>FY22<\/td>\n<td>3,456.67<\/td>\n<td>712.68<\/td>\n<td>54.96<\/td>\n<td>9.50<\/td>\n<\/tr>\n<tr>\n<td>FY23<\/td>\n<td>3,841.28<\/td>\n<td>587.98<\/td>\n<td>45.89<\/td>\n<td>7.00<\/td>\n<\/tr>\n<tr>\n<td>FY24<\/td>\n<td>4,293.31<\/td>\n<td>816.17<\/td>\n<td>64.77<\/td>\n<td>51.00<\/td>\n<\/tr>\n<tr>\n<td>FY25<\/td>\n<td>4,742.60<\/td>\n<td>920.39<\/td>\n<td>73.53<\/td>\n<td>28.00<\/td>\n<\/tr>\n<tr>\n<td>FY26<\/td>\n<td>5,624.93<\/td>\n<td>1,056.00<\/td>\n<td>84.51<\/td>\n<td>28.00<\/td>\n<\/tr>\n<\/table>\n<p>FY26 revenue growth was 18.6%, faster than the four-year average of 12.9%, and net profit moved up 14.7%. EPS rose from Rs 64.77 in FY24 to Rs 84.51 in FY26. The FY27 outlook for the Ajanta Pharma price target depends on whether that EPS estimate keeps compounding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margins_and_the_Latest_Quarter\"><\/span><strong>Margins and the Latest Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ajanta Pharma converted 18.8% of FY26 revenue into net profit, against 19.4% in FY25, within a five-year range of 15.3% to 20.6%. EBITDA margin was 27.9% in FY26 versus 28.5% in FY25.<\/p>\n<p>In the September 2026 quarter, revenue was Rs 1,832 crore, up 29.6% from the same quarter a year earlier, while net profit of Rs 388.14 crore was up 49.2%. EBITDA came in at Rs 584.95 crore, up 51.1% year on year. The next quarterly result is the first test of whether the earnings assumption behind the Ajanta Pharma stock target holds.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Cash_Flow\"><\/span><strong>Balance Sheet and Cash Flow<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Debt to equity stands at 0.03, and shareholders&#8217; equity grew from Rs 3,264 crore in FY22 to Rs 4,527 crore in FY26. Operating cash flow in FY26 was Rs 529.19 crore against capital expenditure of Rs 365.16 crore, leaving free cash flow of Rs 164.03 crore, or 0.4% of the current market capitalisation. In FY25 free cash flow was Rs 839.31 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Check_for_the_Ajanta_Pharma_Stock_Target_PE_Price_to_Book_and_ROE\"><\/span><strong>Valuation Check for the Ajanta Pharma Stock Target: PE, Price to Book and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At a PE of 32.50 against an industry PE of 40.65, Ajanta Pharma trades at a discount to its industry. Price to book is 8.45 on a book value of Rs 388.78 per share, and return on equity is 25.99%. A PE of 32.50 equals an earnings yield of 3.1%, and the FY26 dividend of Rs 28.00 per share gives a yield of 0.86%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Shareholding_Pattern_and_Institutional_Holding\"><\/span><strong>Shareholding Pattern and Institutional Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Promoters held 63.47% of Ajanta Pharma in September 2026, and promoter holding fell from 66.25% in September 2025 to 63.47% in September 2026. Foreign institutional investors (FII) held 7.63% and domestic institutions (DII) held 21.94%, which puts total institutional holding at 29.57%. FII holding fell from 8.53% in September 2025 to 7.63% in September 2026. Public shareholders own the remaining 6.96%. A meaningful institutional holding adds a layer of research coverage and trading depth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_Share_Price_Targets_for_the_Short_Term_and_12_Months\"><\/span><strong>Ajanta Pharma Share Price Targets for the Short Term and 12 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Ajanta_Pharma_Stock_Target_Levels_Technical_Setup\"><\/span><strong>Short Term Ajanta Pharma Stock Target Levels: Technical Setup<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 3,355.80 on 16 November 2026, Ajanta Pharma trades below its 50-day simple moving average of Rs 3,436.12 and above its 200-day exponential moving average of Rs 3,224.68. The 14-day RSI reads 50.2, which is neutral territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 3,436.12 (50-day simple moving average) and the nearest support is Rs 3,224.68 (200-day exponential moving average). A sustained move above Rs 3,436.12 would improve the short-term setup, while a close below Rs 3,224.68 would shift attention to the next support.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Ajanta_Pharma_Target_Price_for_2027\"><\/span><strong>12 Month Ajanta Pharma Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month target of Rs 3,752 means a move of 11.8% up from Rs 3,355.80 over the next 12 months. It would still leave the stock 1.2% below its 52-week high of Rs 3,796.00. Anyone checking the Ajanta Pharma share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_EPS_Growth_and_PE_Multiple_Change_the_Ajanta_Pharma_Target_Price\"><\/span><strong>How EPS Growth and PE Multiple Change the Ajanta Pharma Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>EPS Growth<\/th>\n<th>PE 26.00<\/th>\n<th>PE 32.50<\/th>\n<th>PE 37.38<\/th>\n<\/tr>\n<tr>\n<td>0.0% (EPS Rs 101.06)<\/td>\n<td>Rs 2,628<\/td>\n<td>Rs 3,284<\/td>\n<td>Rs 3,778<\/td>\n<\/tr>\n<tr>\n<td>14.2% (EPS Rs 115.44)<\/td>\n<td>Rs 3,001<\/td>\n<td>Rs 3,752<\/td>\n<td>Rs 4,315<\/td>\n<\/tr>\n<tr>\n<td>20.2% (EPS Rs 121.50)<\/td>\n<td>Rs 3,159<\/td>\n<td>Rs 3,949<\/td>\n<td>Rs 4,542<\/td>\n<\/tr>\n<\/table>\n<p>Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Ajanta Pharma price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Downside_Risk_for_Ajanta_Pharma_Stock_Target_in_2027\"><\/span><strong>Bull Case and Downside Risk for Ajanta Pharma Stock Target in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_4542\"><\/span><strong>Bull Case Rs 4,542<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case Ajanta Pharma price target needs EPS growth of 20.2%, which lifts forward EPS to Rs 121.50, and a PE multiple that rises 15% to 37.38. That gives Rs 4,542, 35.3% above the current price and above the 52-week high of Rs 3,796.00, so the stock would have to set a fresh 52-week high.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Downside_Risk_Level_Rs_2628\"><\/span><strong>Downside Risk Level Rs 2,628<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The downside risk level is not a target. It assumes EPS stays flat at Rs 101.06 and the PE falls 20% to 26.00. That gives Rs 2,628, 21.7% below the current price and above the 52-week low of Rs 2,445.80.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Scenario<\/th>\n<th>EPS Growth<\/th>\n<th>PE Multiple<\/th>\n<th>Price (Rs)<\/th>\n<th>Change vs CMP<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>20.2%<\/td>\n<td>37.38<\/td>\n<td>Rs 4,542<\/td>\n<td>+35.3%<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>14.2%<\/td>\n<td>32.50<\/td>\n<td>Rs 3,752<\/td>\n<td>+11.8%<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk<\/td>\n<td>0.0%<\/td>\n<td>26.00<\/td>\n<td>Rs 2,628<\/td>\n<td>-21.7%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Ajanta_Pharma_Target_Price_for_2027\"><\/span><strong>Key Risks to the Ajanta Pharma Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Growth_Slowdown_Risk_for_the_Ajanta_Pharma_Price_Target\"><\/span><strong>Growth Slowdown Risk for the Ajanta Pharma Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue in the September 2026 quarter was up 29.6% year on year, and FY26 revenue growth was 18.6%. If growth slows from here, the EPS estimate behind the Ajanta Pharma stock target will need revising.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_and_Size_Risk\"><\/span><strong>Liquidity and Size Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ajanta Pharma has a market capitalisation of Rs 41,042 crore. Institutional holding is 29.57%, and promoters hold 63.47%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Margin_Risk\"><\/span><strong>Valuation and Margin Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net margin was 18.8% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 32.50 versus an industry PE of 40.65, a de-rating toward the downside-risk PE of 26.00 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Market_and_Technical_Risk\"><\/span><strong>Market and Technical Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Technical indicators add short-term risk: the 14-day RSI is 50.2 and the MACD sits above its signal line. A broad fall in the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> or the <a href=\"https:\/\/univest.in\/indices\/sensex\/sensex-share-price-today\">Sensex<\/a> can override company fundamentals for weeks at a time.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Ajanta_Pharma\"><\/span><strong>How to Invest in Ajanta Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start with the live price and volume. Any Ajanta Pharma share price target is only as current as the data behind it, and the data here is as of 16 November 2026, so refresh the Rs 3,355.80 price before acting on any level.<\/p>\n<p>Next, review the fundamentals yourself. The Univest Screener lets you check Ajanta Pharma&#8217;s PE, ROE, debt and shareholding in one place.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Ajanta Pharma fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<p>Then compare the three Ajanta Pharma target price scenarios with your own view. If you expect EPS growth below 14.2%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.<\/p>\n<p>Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.<\/p>\n<p>Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Ajanta Pharma live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Ajanta Pharma share price target for 2027 is Rs 3,752 in the base case, with Rs 4,542 as the bull case. The support for that view is arithmetic you can check: EPS grew 14.2% a year over FY24 to FY26, and the stock trades at a PE of 32.50. The risks are equally concrete, including a valuation that can de-rate if growth disappoints and a downside scenario that cuts the price 22% if earnings stall. Use these numbers as a framework for judging the Ajanta Pharma price target, check them against the latest filings, and size any position to your own risk appetite.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Ajanta_Pharma_Share_Price_Target_2027\"><\/span><strong>FAQs on Ajanta Pharma Share Price Target 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Ajanta_Pharma_share_price_target_for_2027\"><\/span><strong>What is the Ajanta Pharma share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The base-case Ajanta Pharma share price target for 2027 is Rs 3,752, which is 11.8% above the price of Rs 3,355.80 on 16 November 2026. The bull case is Rs 4,542 and the downside risk level, which is not a target, is Rs 2,628. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Ajanta_Pharma_share_price_today\"><\/span><strong>What is the Ajanta Pharma share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 16 November 2026, 1:32 PM IST, Ajanta Pharma (NSE: AJANTPHARM) trades at Rs 3,355.80, up 2.19% on the day. That is 11.6% below the 52-week high of Rs 3,796.00 and 37.2% above the 52-week low of Rs 2,445.80. The market capitalisation of Rs 41,042 crore places it among mid-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Ajanta_Pharma_a_buy_or_sell_at_the_current_price\"><\/span><strong>Is Ajanta Pharma a buy or sell at the current price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The data points both ways. On the positive side, EPS has grown 14.2% a year over FY24 to FY26 and the base case implies 11.8% upside; on the cautious side, the stock sits 11.6% below its 52-week high and can de-rate if growth disappoints, and the downside risk level of Rs 2,628 is 22% below the current price. Whether Ajanta Pharma fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_bull_case_target_and_downside_risk_level_for_Ajanta_Pharma_shares\"><\/span><strong>What are the bull case target and downside risk level for Ajanta Pharma shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case in the Ajanta Pharma share price target for 2027 is Rs 4,542, which assumes 20.2% EPS growth and a PE of 37.38, a 15% re-rating from today&#8217;s multiple. That is 35.3% above the current price and above the 52-week high of Rs 3,796.00, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 2,628, which assumes flat EPS and a PE of 26.00, 20% lower than today. It sits 21.7% below the current price and above the 52-week low of Rs 2,445.80, and it marks a risk to watch, not a target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Ajanta_Pharma_price_target\"><\/span><strong>What are the main risks to the Ajanta Pharma price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Four risks matter most for the Ajanta Pharma share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 41,042 crore, the stock is usually liquid, though exits can take longer than entries in a falling market. A fall to the downside-risk PE of 26.00 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_ratio_of_Ajanta_Pharma_and_how_does_it_compare_with_the_industry\"><\/span><strong>What is the PE ratio of Ajanta Pharma and how does it compare with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PE ratio of Ajanta Pharma is 32.50, against an industry PE of 40.65, which is a discount to the industry. Price to book is 8.45 and return on equity is 25.99%, and the PE equals an earnings yield of 3.1%. The base case holds the PE unchanged, so the Ajanta Pharma share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Ajanta_Pharma_and_what_is_the_promoter_holding\"><\/span><strong>Who owns Ajanta Pharma, and what is the promoter holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoters held 63.47% of Ajanta Pharma in September 2026. FII held 7.63%, DII held 21.94% and the public held 6.96%. Together the two institutional groups hold 29.57%. Shareholding is filed every quarter, so it is worth rechecking after each result.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Ajanta_Pharmas_latest_quarterly_results\"><\/span><strong>What were Ajanta Pharma&#8217;s latest quarterly results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the September 2026 quarter, Ajanta Pharma reported revenue of Rs 1,832 crore (up 29.6% year on year) and net profit of Rs 388.14 crore (up 49.2%). For comparison, FY26 full-year revenue growth was 18.6% and net profit moved up 14.7%. Each new quarter either supports or weakens the EPS growth of 14.2% assumed in the base case.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Ajanta Pharma share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The base-case Ajanta Pharma share price target for 2027 is Rs 3,752, which is 11.8% above the price of Rs 3,355.80 on 16 November 2026. The bull case is Rs 4,542 and the downside risk level, which is not a target, is Rs 2,628. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.\"}},{\"@type\":\"Question\",\"name\":\"What is the Ajanta Pharma share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 16 November 2026, 1:32 PM IST, Ajanta Pharma (NSE: AJANTPHARM) trades at Rs 3,355.80, up 2.19% on the day. That is 11.6% below the 52-week high of Rs 3,796.00 and 37.2% above the 52-week low of Rs 2,445.80. The market capitalisation of Rs 41,042 crore places it among mid-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.\"}},{\"@type\":\"Question\",\"name\":\"Is Ajanta Pharma a buy or sell at the current price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The data points both ways. On the positive side, EPS has grown 14.2% a year over FY24 to FY26 and the base case implies 11.8% upside; on the cautious side, the stock sits 11.6% below its 52-week high and can de-rate if growth disappoints, and the downside risk level of Rs 2,628 is 22% below the current price. Whether Ajanta Pharma fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.\"}},{\"@type\":\"Question\",\"name\":\"What are the bull case target and downside risk level for Ajanta Pharma shares?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The bull case in the Ajanta Pharma share price target for 2027 is Rs 4,542, which assumes 20.2% EPS growth and a PE of 37.38, a 15% re-rating from today's multiple. That is 35.3% above the current price and above the 52-week high of Rs 3,796.00, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 2,628, which assumes flat EPS and a PE of 26.00, 20% lower than today. It sits 21.7% below the current price and above the 52-week low of Rs 2,445.80, and it marks a risk to watch, not a target.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks to the Ajanta Pharma price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Four risks matter most for the Ajanta Pharma share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 41,042 crore, the stock is usually liquid, though exits can take longer than entries in a falling market. A fall to the downside-risk PE of 26.00 would cut the price even if earnings hold.\"}},{\"@type\":\"Question\",\"name\":\"What is the PE ratio of Ajanta Pharma and how does it compare with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The PE ratio of Ajanta Pharma is 32.50, against an industry PE of 40.65, which is a discount to the industry. Price to book is 8.45 and return on equity is 25.99%, and the PE equals an earnings yield of 3.1%. The base case holds the PE unchanged, so the Ajanta Pharma share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.\"}},{\"@type\":\"Question\",\"name\":\"Who owns Ajanta Pharma, and what is the promoter holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Promoters held 63.47% of Ajanta Pharma in September 2026. FII held 7.63%, DII held 21.94% and the public held 6.96%. Together the two institutional groups hold 29.57%. Shareholding is filed every quarter, so it is worth rechecking after each result.\"}},{\"@type\":\"Question\",\"name\":\"What were Ajanta Pharma's latest quarterly results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the September 2026 quarter, Ajanta Pharma reported revenue of Rs 1,832 crore (up 29.6% year on year) and net profit of Rs 388.14 crore (up 49.2%). For comparison, FY26 full-year revenue growth was 18.6% and net profit moved up 14.7%. Each new quarter either supports or weakens the EPS growth of 14.2% assumed in the base case.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ajanta Pharma share price target 2027: base Rs 3,752, bull Rs 4,542, downside risk level Rs 2,628, built from reported earnings, valuation and shareholding data.<\/p>\n","protected":false},"author":38,"featured_media":348449,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1019],"class_list":["post-348450","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["348449"],"rank_math_title":["Ajanta Pharma Share Price Target 2027: 11.8% Upside and Risks"],"rank_math_description":["The Ajanta Pharma share price target for 2027 is Rs 3,752 against a price of Rs 3,355.80. Bull case, downside risk, earnings trend and risks explained. November 2026."],"rank_math_focus_keyword":["Ajanta Pharma share price target | Density Target: 1.2 to 1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/ajanta-pharma-share-price-target-2027-is-rs-3-752-realistic-bull-case-points-to.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/348450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=348450"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/348450\/revisions"}],"predecessor-version":[{"id":348452,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/348450\/revisions\/348452"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/348449"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=348450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=348450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=348450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}